Graphic: corner
spacer
Graphic: corner
spacer spacer
nav left edge
nav right edge
spacer Supreme Court rules on gene patents
June 14, 2013
The June 13, 2013 United States Supreme Court ruling in the so-called "Myriad" case has drawn much attention and confusion in the media. This ruling held that "a naturally occurring DNA segment is a product of nature and not patent eligible". However, the Myriad decision does not address or invalidate diagnostic method patent claims.  Optigen wants to emphasize that the Myriad decision does not address diagnostic method patent claims, as the case itself states: "It is important to note what is not implicated by this decision... there are no method claims before this Court." Therefore, the Myriad decision is not relevant to patent claims which cover diagnostic methods. Such “methods” patents are not affected by this ruling and are therefore still valid, including Optigen tests such as the patented prcd tests.
 
Here is the actual decision, from: http://www.supremecourt.gov/opinions/12pdf/12-398_1b7d.pdf


spacer
Graphic: footer bar left
OptiGen®, LLC · Cornell Business & Technology Park · 767 Warren Road, Suite 300 · Ithaca, New York 14850
Tel: 607 257 0301 · Fax: 607 257 0353 · email: genetest@optigen.com or optigen@clarityconnect.com
Graphic: footer bar right
spacer spacer
spacer
spacer
spacer